UroGen Pharma Ltd. URGN
24.75 USD -0.98 (-3.81%)
At closeNov 6, 2026, 5:53 PM EST
24.00 -0.75 -3.03%
After hours · Nov 6, 5:53 PM ET
24.40 Day range 26.34
16.50 52-week range 50.81
- YTD
- +5.68%
- 1 year
- +5.14%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 61.71 +149.4% upside
Now 24.75
- Target (low)
- 56.00
- Target (mean)
- 61.71
- Target (high)
- 75.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.425 | -0.01 – 0.77 | -0.53 | +180.2% | 108.59M | +187.0% | 6 |
| Next quarter | 0.402 | 0.01 – 0.77 | -0.47 | +185.5% | 113.92M | +123.6% | 5 |
| Current year | -0.20333 | -0.83 – 0.20 | -3.19 | +93.6% | 321.90M | +193.2% | 6 |
| Next year | 2.76 | 1.05 – 5.19 | -0.20333 | +1457.4% | 531.04M | +65.0% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | Guggenheim | Maintained | Buy | Buy |
| Oct 19, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 5, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jul 21, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 16, 2026 | Oppenheimer | Maintained | Outperform | Outperformer |
| Jun 3, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 11, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 7, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 31, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Mar 2, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Jan 23, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Jan 5, 2026 | D. Boral Capital | Maintained | Buy | Buy |
| Oct 27, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 27, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Oct 3, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Aug 19, 2025 | Piper Sandler | Initiated | — | Overweight |
| Aug 11, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 7, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Aug 5, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Jul 8, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 7, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Jun 16, 2025 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Jun 13, 2025 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Jun 13, 2025 | Guggenheim | Maintained | Buy | Buy |
| Jun 13, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Jun 12, 2025 | D. Boral Capital | Maintained | Buy | Buy |
| Jun 3, 2025 | Oppenheimer | Maintained | Outperform | Outperform |